Latest Recruitment News

Astron Corporation is set to redomicile from Hong Kong to Australia, establishing a new Australian parent company and simplifying shareholder engagement. This move aims to align governance with local standards and boost investor confidence.

HeraMED has partnered with RMIT University and the Digital Health CRC to develop AI-driven maternity care models focused on culturally diverse populations, aiming to improve pre-term delivery risk prediction and personalised care.

EDU Holdings reports a remarkable 118% increase in total student enrolments at its Ikon Institute for Trimester 2, 2025, driven by strong demand and new course offerings amid a shifting regulatory landscape.

Dimerix has reached a key milestone by dosing 200 adult patients in its Phase 3 ACTION3 trial for FSGS, progressing steadily toward full recruitment expected in late 2025.

Syntara Limited is set to reveal fresh interim results from its Phase 2 trial of SNT-5505, targeting myelofibrosis, during an investor webinar ahead of a major European hematology conference.

Bowen Coking Coal is set to transition its Burton Mine Complex to an owner-operator model from July 1, 2025, aiming to increase production and reduce costs. This strategic shift marks a new chapter in Bowen’s operational control and growth ambitions.

Paradigm Biopharmaceuticals has reached key milestones in its global Phase 3 trial for knee osteoarthritis, activating its first Australian clinical site and enrolling the first patient. With multiple sites in Australia and the US preparing for recruitment, the trial is advancing steadily toward critical data readouts.

Lumos Diagnostics has reached 50% recruitment of bacterial positive patients in its pivotal FebriDx CLIA waiver clinical study, setting the stage for a planned FDA submission in late 2025 and unlocking a substantial US market opportunity.

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.

Dimerix has activated the first clinical trial site in Japan for its pivotal Phase 3 ACTION3 study targeting FSGS, triggering a significant milestone payment from its Japanese partner FUSO Pharmaceutical.

Meeka Metals is on track to commission its upgraded processing plant at the Murchison Gold Project by June 2025, aiming for first gold production shortly thereafter. The company has also expanded its workforce accommodations and advanced underground mine preparations.

Regal Partners Limited reported a stellar 2024 with a 141% jump in average funds under management to $14.4 billion and a near tripling of net profit after tax. Strategic acquisitions and offshore expansion underpin its growth trajectory.